FDA Brief

Warning letters Drugs

FDA warning letter to

Intas Pharmaceuticals Limited

High riskIssued Mar 30Posted Apr 28Center for Drug Evaluation and Research (CDER)

FDA warns Intas Pharmaceuticals' Dehradun, India plant over weak out-of-spec investigations and untracked batch-record edits for its tablets.

What happened

FDA inspected the Intas drug manufacturing site in Dehradun from September 8 to 17, 2025. Investigators found that since 2023 the company kept getting stability test results showing tablets were below the potency (assay) specification, and its investigations and corrective actions did not fix the problem; the company recalled some batches. FDA also found that a quality assurance employee asked a software vendor to change a 'Dispensed by' employee ID in an electronic batch record, and the change appeared in neither the audit trail nor the batch record.

What FDA found

  1. The company did not properly investigate batches whose potency tests fell below specification, and its fixes did not stop the failures from repeating.

    21 CFR 211.192
  2. It blamed low results on 'product behavior' and never worked out whether its own test method was causing the variation.

    21 CFR 211.192
  3. It invalidated an out-of-spec 12-month stability result for 'solution preparation error' without solid evidence and left that result out of its final report.

    21 CFR 211.192
  4. An employee ID in a batch record was changed at the company's request without any entry in the audit trail.

    21 CFR 211.22
  5. The quality unit had no detailed procedures to control changes made to electronic batch records after a batch was completed.

    21 CFR 211.22

What FDA wants

FDA tells Intas to correct the violations promptly and reply in writing within 15 working days, including a batch impact assessment, an independent third-party review of its investigation and corrective-action systems, a retrospective review of software vendor communications and audit trails, and a plan to give its quality unit authority and resources. FDA says it may withhold approvals and refuse US entry of products from the site until it confirms compliance.

Who should pay attention

  • US distributors and pharmacies selling generic tablets made at this site
  • companies that use this plant as a contract manufacturer
  • quality teams whose electronic batch records are edited by software vendors

This is a summary. Read the original letter on fda.gov.

Intas Pharmaceuticals Limited's FDA history

  1. Intas Pharmaceuticals Limited

    CGMP/Finished Pharmaceuticals/Adulterated

  2. Intas Pharmaceuticals Limited

    CGMP/Finished Pharmaceuticals/Adulterated

Full company page

Similar letters to other companies

  1. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  2. kdc/one Chatsworth, Inc.

    FDA warned kdc/one Chatsworth of CGMP violations in OTC drugs, including missing carcinogen testing and storage temperature failures.

    High risk
  3. ABS Corporation

    ABS Corporation released out-of-specification veterinary drugs and used inadequately tested raw materials, FDA says.

    High risk
  4. Island Kinetics, Inc. d.b.a. CoValence Laboratories

    Island Kinetics (CoValence Laboratories) made OTC acne drugs without process validation and shipped unapproved, misbranded acne products.

    High risk